Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2-advanced breast cancer (ABC).

	Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2-advanced breast cancer (ABC).
	Zhang, Jian 1; Wang, Xiaojia 2; Wang, Xian 3; Hui, Aimin 4; Wu, Zhuli 5; Tian, Ling 6; Xu, Changjiang 7; Yang, Yuchen 7; Zhang, Wenjing 7; Hu, Xichun 1
刊名	CANCER RESEARCH
	2021-07-01
卷号	81
ISSN号	0008-5472
WOS研究方向	Oncology
语种	英语
出版者	AMER ASSOC CANCER RESEARCH
WOS记录号	WOS:000680263501256
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/125096]
专题	中国科学院合肥物质科学研究院
作者单位	1.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 3.Sir Run Run Shaw Hosp, Hangzhou, Peoples R China 4.Fosun Pharma USA Inc, Lexington, MA USA 5.Beijing Fosun Pharmaceut Res & Dev Co Ltd, Beijing, Peoples R China 6.Avanc Pharmaceut Co Ltd, Jinzhou, Peoples R China 7.Beijing Fosun Pharmaceut Res & Dev Co Ltd, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Jian,Wang, Xiaojia,Wang, Xian,et al. Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2-advanced breast cancer (ABC).[J]. CANCER RESEARCH,2021,81.
APA	Zhang, Jian.,Wang, Xiaojia.,Wang, Xian.,Hui, Aimin.,Wu, Zhuli.,...&Hu, Xichun.(2021).Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2-advanced breast cancer (ABC)..CANCER RESEARCH,81.
MLA	Zhang, Jian,et al."Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2-advanced breast cancer (ABC).".CANCER RESEARCH 81(2021).